Literature DB >> 21346256

Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.

Cynthia M Pruss1, Mia Golder, Andrea Bryant, Carol A Hegadorn, Erin Burnett, Kimberly Laverty, Kate Sponagle, Aly Dhala, Colleen Notley, Sandra Haberichter, David Lillicrap.   

Abstract

Type 1 VWD is the mild to moderate reduction of VWF levels. This study examined the mechanisms underlying 2 common type 1 VWD mutations, the severe R1205H and more moderate Y1584C. In vitro biosynthesis was reduced for both mutations in human and mouse VWF, with the effect being more severe in R1205H. VWF knockout mice received hydrodynamic injections of mouse Vwf cDNA. Lower VWF antigen levels were demonstrated in both homozygous and heterozygous forms for both type 1 mutations from days 14-42. Recombinant protein infusions and hydrodynamic-expressed VWF propeptide to antigen ratios demonstrate that R1205H mouse VWF has an increased clearance rate, while Y1584C is normal. Recombinant ADAMTS13 digestions of Y1584C demonstrated enhanced cleavage of both human and mouse VWF115 substrates. Hydrodynamic-expressed VWF shows a loss of high molecular weight multimers for Y1584C compared with wild-type and R1205H. At normal physiologic levels of VWF, Y1584C showed reduced thrombus formation in a ferric chloride injury model while R1205H demonstrated similar thrombogenic activity to wild-type VWF. This study has elucidated several novel mechanisms for these mutations and highlights that the type 1 VWD phenotype can be recapitulated in the VWF knockout hydrodynamic injection model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346256      PMCID: PMC3087484          DOI: 10.1182/blood-2010-08-303727

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Authors:  Paula D James; Colleen Notley; Carol Hegadorn; Jayne Leggo; Angie Tuttle; Shawn Tinlin; Christine Brown; Chandler Andrews; Andrea Labelle; Yvette Chirinian; Lee O'Brien; Maha Othman; Georges Rivard; Dilys Rapson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

2.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

Authors:  Anne Goodeve; Jeroen Eikenboom; Giancarlo Castaman; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Reinhard Schneppenheim; Ulrich Budde; Jorgen Ingerslev; David Habart; Zdena Vorlova; Lars Holmberg; Stefan Lethagen; John Pasi; Frank Hill; Mohammad Hashemi Soteh; Luciano Baronciani; Christer Hallden; Andrea Guilliatt; Will Lester; Ian Peake
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

3.  ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.

Authors:  Cynthia M Pruss; Colleen R P Notley; Carol A Hegadorn; Lee A O'Brien; David Lillicrap
Journal:  Br J Haematol       Date:  2008-11       Impact factor: 6.998

4.  Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease.

Authors:  M Bowman; G Mundell; J Grabell; W M Hopman; D Rapson; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2008-10-04       Impact factor: 5.824

5.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

6.  The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.

Authors:  J Stakiw; M Bowman; C Hegadorn; C Pruss; C Notley; E Groot; P J Lenting; D Rapson; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2007-10-08       Impact factor: 5.824

7.  Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

Authors:  Giancarlo Castaman; Stefan Lethagen; Augusto B Federici; Alberto Tosetto; Anne Goodeve; Ulrich Budde; Javier Batlle; Dominique Meyer; Claudine Mazurier; Edith Fressinaud; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; John Pasi; Frank Hill; Ian Peake; Francesco Rodeghiero
Journal:  Blood       Date:  2008-01-29       Impact factor: 22.113

8.  Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa.

Authors:  Isabelle Marx; Olivier D Christophe; Peter J Lenting; Alain Rupin; Marie-Odile Vallez; Tony J Verbeuren; Cécile V Denis
Journal:  Blood       Date:  2008-05-16       Impact factor: 22.113

9.  The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation.

Authors:  Fumiaki Banno; Anil K Chauhan; Koichi Kokame; Jin Yang; Shigeki Miyata; Denisa D Wagner; Toshiyuki Miyata
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

10.  C1584 in von Willebrand factor is necessary for enhanced proteolysis by ADAMTS13 in vitro.

Authors:  S Keeney; P Grundy; P W Collins; D J Bowen
Journal:  Haemophilia       Date:  2007-07       Impact factor: 4.287

View more
  21 in total

1.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.

Authors:  Ashley Cartwright; Simon J Webster; Annika de Jong; Richard J Dirven; Lisa D S Bloomer; Ahlam M Al-Buhairan; Ulrich Budde; Christer Halldén; David Habart; Jenny Goudemand; Ian R Peake; Jeroen C J Eikenboom; Anne C Goodeve; Daniel J Hampshire
Journal:  Blood Adv       Date:  2020-07-14

3.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

4.  Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.

Authors:  C M Pruss; M Golder; A Bryant; C Hegadorn; S Haberichter; D Lillicrap
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

Review 5.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

6.  A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria.

Authors:  Niamh O'Regan; Kristina Gegenbauer; Jamie M O'Sullivan; Sanaz Maleki; Teresa M Brophy; Niall Dalton; Alain Chion; Padraic G Fallon; Georges E Grau; Ulrich Budde; Owen P Smith; Alister G Craig; Roger J S Preston; James S O'Donnell
Journal:  Blood       Date:  2015-10-28       Impact factor: 22.113

Review 7.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

8.  The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen.

Authors:  Laura L Swystun; Kenichi Ogiwara; Jesse D Lai; Juha R M Ojala; Orla Rawley; Fanny Lassalle; Colleen Notley; Olle Rengby; Alison Michels; Kate Nesbitt; Karl Tryggvason; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-06-20       Impact factor: 5.824

9.  The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

Authors:  Natalia Rydz; Laura L Swystun; Colleen Notley; Andrew D Paterson; J Jacob Riches; Kate Sponagle; Boonchai Boonyawat; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  Blood       Date:  2013-03-25       Impact factor: 22.113

10.  Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation.

Authors:  Yasuaki Shida; Natalia Rydz; David Stegner; Christine Brown; Jeffrey Mewburn; Kate Sponagle; Ozge Danisment; Bredon Crawford; Barbara Vidal; Carol A Hegadorn; Cynthia M Pruss; Bernhard Nieswandt; David Lillicrap
Journal:  Blood       Date:  2014-07-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.